Vaccination against Covid-19 reduces 90% the risk of hospitalization and death in people over 50 and seems to be equally effective against the Delta variant, However, we still lack perspective, according to a large French study in real life published on October 11, 2021 and announced by AFP.
To reach this conclusion, the Epi-Phare researchers compared data from 11 million people over 50 vaccinated with those of 11 million unvaccinated people in the same age group, over a period from December 27, 2020 (start of vaccination in France) to July 20, 2021.
From the 14th day after the injection of the second dose, the researchers observed “a reduction in the risk of hospitalization greater than 90%”. This observation applies to the vaccines from Pfizer / BioNtech, Moderna and AstraZeneca (the fourth authorized in France, that of Janssen, was later authorized, was used in smaller proportions and is therefore not included in the study. ).
“This reduction is of the same order of magnitude, for the risk of death during hospitalization for Covid-19”, according to Epi-Phare. This efficacy in severe forms of the disease “does not seem to decrease over the available follow-up period, which went up to 5 months”.
For identify the impact of the Delta variant, now dominant, researchers have estimated, in a specific way, the reduction in the risk of hospitalization, during the period when it gained momentum in France, from June 20 (so one month before the closing of the study).
They found results comparable to previous periods: efficiency 84% among those aged 75 and over and 92% among those aged 50-74. This makes it possible to provide “initial elements”, but “this period remains very short to assess the real impact of vaccination on this variant”, warn the researchers, who are continuing their study to find out more. These French data confirm other observations made in real life elsewhere in the world.
October 14, 2021 at 9:59 a.m.
Edited October 14, 2021 at 11:44 a.m.